A detailed history of Merit Financial Group, LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Merit Financial Group, LLC holds 43,800 shares of IBRX stock, worth $213,306. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,800
Previous 43,819 0.04%
Holding current value
$213,306
Previous $276,000 41.3%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$3.32 - $6.7 $63 - $127
-19 Reduced 0.04%
43,800 $162,000
Q2 2024

Aug 13, 2024

BUY
$4.82 - $9.15 $33 - $64
7 Added 0.02%
43,819 $276,000
Q1 2024

May 06, 2024

BUY
$3.23 - $6.17 $38 - $74
12 Added 0.03%
43,812 $235,000
Q3 2023

Nov 07, 2023

BUY
$1.29 - $3.1 $25,800 - $62,000
20,000 Added 84.03%
43,800 $74,000
Q1 2023

Apr 24, 2023

BUY
$1.35 - $4.78 $32,130 - $113,764
23,800 New
23,800 $43,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.95B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Merit Financial Group, LLC Portfolio

Follow Merit Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Merit Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Merit Financial Group, LLC with notifications on news.